Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 févr. 2024 22h30 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 févr. 2024 15h20 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease,...
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
24 janv. 2024 08h35 HE
|
Immix Biopharma, Inc.
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
04 janv. 2024 09h34 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined...
Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
18 déc. 2023 09h39 HE
|
Immix Biopharma, Inc.
Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine, 2019 Dr. Radic is a recognized...
Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
11 déc. 2023 09h36 HE
|
Immix Biopharma, Inc.
100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6...
Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
30 nov. 2023 09h46 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) a clinical-stage biopharmaceutical company pioneering personalized therapies...
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
22 nov. 2023 09h19 HE
|
Immix Biopharma, Inc.
LOS ANGELES, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company advancing personalized therapies...
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
21 nov. 2023 09h46 HE
|
Immix Biopharma, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain...
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
21 nov. 2023 09h46 HE
|
Immix Biopharma, Inc.
NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients previously dosed with NXC-201 ex-U.S.First CAR-T program for light-chain...